Cost-effectiveness analysis reveals toripalimab plus chemotherapy improves outcomes in extensive-stage small cell lung cancer, suggesting healthcare system benefits.
Objective To evaluate the cost-effectiveness of toripalimab combined with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: